Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicenter, Randomized Open-Label Study To Determine the Efficacy of Lenalidomide (Revlimid®) Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma

NCT00875667 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT00875667
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00875667 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicenter, Randomized Open-Label Study To Determine the Efficacy of Lenalidomide (Revlimid®) Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Lead sponsor
Celgene
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2009
Completion date
October 9, 2018
Enrollment
254 (actual)
Sites
97

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, mantle-cell, mantle cell lymphoma